Cell Therapeutics, Inc. (NASDAQ: CTIC) is focused on leading the biopharmaceutical industry with their diversified portfolio of proprietary oncology drugs. They manage each and every aspect of the manufacturing process, but outsource their clinical and commercial active pharmaceutical ingredient (API) and finished product (FP) production activities to superior contract manufacturing organizations, both in the US and in Europe. For further information, visit the Company’s web site at www.ctiseattle.com.
- 18 years ago
QualityStocks
Cell Therapeutics, Inc. (NASDAQ: CTIC)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Massimo Group (NASDAQ: MAMO) Terminates Proposed FST Acquisition, Refocuses on Internal Security Technology Development
Massimo Group (NASDAQ: MAMO), a manufacturer and distributor of powersports vehicles and mobility solutions, announced it has terminated its…
-
QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid…
-
QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Engages Nanosoft to Advance ONC010 Development Program
This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.…